Skip to main content
VM

Vessi Medical

Vessi Medical has developed a patent-protected cryo spray technology specifically for ablating urological tissues in hollow and humid organs, offering a minimally invasive alternative to traditional surgical procedures. This approach reduces complications, eliminates the need for general anesthesia in some cases, and lowers healthcare costs associated with the treatment of Non-Muscle-Invasive Bladder Cancer (NMIBC).

Gavà, IsraelFounded 20155300+ followers
Updated 20 months ago

Funding

$18.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.

A
Funding rounds are not available yet.

Founders

Product

Problem

Current surgical procedures for treating urological tissues in hollow and humid organs, such as the bladder, are often invasive, costly, and require general anesthesia, leading to significant complications and reduced patient quality of life. These procedures often necessitate hospital stays and may need to be repeated, further increasing healthcare costs.

Solution

Vessi Medical offers a minimally invasive cryo spray technology specifically designed for ablating urological tissues within hollow and humid organs. The Vessi System comprises a standalone console and a disposable device for transurethral insertion, enabling targeted cryotherapy without the need for general anesthesia in some cases. This non-contact ablation technique effectively treats the targeted tissue and surrounding areas while minimizing the risk of complications associated with traditional surgical methods. The system provides effective visualization inside hollow organs, even in mixed liquid and gas environments, ensuring precise and controlled treatment.

Target Audience

The primary target audience includes urologists and medical facilities seeking minimally invasive and cost-effective solutions for treating urological tissues, specifically Non-Muscle-Invasive Bladder Cancer (NMIBC).

Features

  • Standalone console and disposable catheter for transurethral insertion
  • Non-contact cryo spray technology for targeted tissue ablation
  • Real-time visualization within hollow organs during cryotherapy
  • Optimized cooling temperature and pressure for effective treatment
  • Flexible design suitable for office procedures without general anesthesia in some cases
  • Reduced risk of complications compared to traditional surgical methods
This profile is AI-generated and may contain inaccuracies.